LIDOCAINE HYDROCHLORIDE INJECTION 100 MG / 5 ML — DIN 02522268
LIDOCAINE HYDROCHLORIDE : 100 MG / 5 ML · LABORATOIRE AGUETTANT · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is LIDOCAINE HYDROCHLORIDE INJECTION?
LIDOCAINE HYDROCHLORIDE INJECTION 100 MG / 5 ML contains LIDOCAINE HYDROCHLORIDE : 100 MG / 5 ML. It is listed in the Health Canada Drug Product Database under DIN 02522268, held by LABORATOIRE AGUETTANT, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 19-Apr-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is LIDOCAINE HYDROCHLORIDE INJECTION used for?
Lidocaine Hydrochloride Injection is indicated for production of local or regional anesthesia by: infiltration techniques including percutaneous injection, peripheral nerve block techniques such as brachial plexus and intercostal blocks, and central neural techniques including epidural and caudal blocks, when the accepted procedures for these techniques, as described in standard textbooks, are observed.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Lidocaine cost around the world?
Lidocaine is listed on 14 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 25 | 121 | USD███.██ |
| United Kingdom | hospital | 22 | 22 | GBP███.██ |
| United Arab Emirates | public | 11 | 16 | AED███.██ |
| Bahrain | retail (max) | 11 | 14 | BHD███.██ |
| South Africa | single exit price | 7 | 12 | ZAR███.██ |
| Greece | producer price (ex-factory) | 9 | 9 | EUR███.██ |
| Saudi Arabia | public | 6 | 9 | SAR███.██ |
| Morocco | PPV (public price) | 8 | 8 | MAD███.██ |
| Austria | KVP (Kassenverkaufspreis) | 4 | 4 | EUR███.██ |
| Australia | ex-manufacturer | 3 | 3 | AUD███.██ |
| Luxembourg | reimbursement | 3 | 3 | EUR███.██ |
| Iceland | max wholesale | 2 | 2 | ISK███.██ |
| Czechia | max producer price (ex-factory) | 1 | 1 | CZK███.██ |
| Lebanon | public price (USD, Decision 119/1) | 1 | 1 | USD███.██ |
225 pack listings across 113 brand entries and 13 price bases, refreshed 08 Sep 2026. Ranges span every Lidocaine pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Lidocaine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
8 holders have a Canadian DIN containing Lidocaine, across 13 DINs, of which 4 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| BAXTER CORPORATION | 3 | 1 | 0.4% LIDOCAINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION, LIDOCAINE HCL 0.2% AND DEXTROSE 5% INJ, LIDOCAINE HCL 0.8% AND 5% DEXTROSE INJ | Sourceable in Canada |
| ASPEN PHARMACARE CANADA INC. | 1 | 1 | XYLOCARD | Sourceable in Canada |
| LABORATOIRE AGUETTANT | 1 | 1 | LIDOCAINE HYDROCHLORIDE INJECTION | Sourceable in Canada |
| PFIZER CANADA ULC | 1 | 1 | LIDOCAINE HYDROCHLORIDE INJECTION USP | Sourceable in Canada |
| B. BRAUN MEDICAL INC | 3 | 0 | LIDOCAINE HCL AND DEXTROSE 5% INJ USP, LIDOCAINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION USP | No marketed DIN |
| HOSPIRA HEALTHCARE ULC | 2 | 0 | 0.4% LIDOCAINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION USP, LIDOCAINE 0.2% IN 5% DEXTROSE INJ | No marketed DIN |
| ASTRA PHARMA INC. | 1 | 0 | XYLOCARD ONE GM ADDITIVE UNIT 20% INJ | No marketed DIN |
| INTERNATIONAL MEDICATION SYSTEMS LTD. | 1 | 0 | LIDOCAINE HCL INJ 20MG/ML | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 100 MG / 5 ML |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | sterile 5 ml or 10 ml polypropylene pre-filled syringe, individually packaged in a blister |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Lidocaine |
|---|---|
| ATC code | C01BB01 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02522268 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2522268 |
| Brand name | LIDOCAINE HYDROCHLORIDE INJECTION |
| Generic / active ingredient | LIDOCAINE HYDROCHLORIDE : 100 MG / 5 ML |
| Market authorization holder | LABORATOIRE AGUETTANT |
| Health Canada schedule | Ethical |
| ATC code | C01BB01 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C01BB |
| Current status | MARKETED |
| Status date | 19-Apr-2023 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Lidocaine in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Anticipated — reported by HIKMA CANADA LIMITED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
4 of 13 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| 0.4% LIDOCAINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION | 4 MG | SOLUTION | BAXTER CORPORATION | MARKETED | 00828602 |
| LIDOCAINE HYDROCHLORIDE INJECTION USP | 20 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | 00436208 |
| XYLOCARD | 100 MG / 5 ML | SOLUTION | ASPEN PHARMACARE CANADA INC. | MARKETED | 00001937 |
| 0.4% LIDOCAINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION USP | 4 MG | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | 00478288 |
| LIDOCAINE 0.2% IN 5% DEXTROSE INJ | 50 MG | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | 00478296 |
| LIDOCAINE HCL 0.2% AND DEXTROSE 5% INJ | 50 MG | SOLUTION | BAXTER CORPORATION | CANCELLED POST MARKET | 00828599 |
| LIDOCAINE HCL 0.8% AND 5% DEXTROSE INJ | 50 MG | SOLUTION | BAXTER CORPORATION | CANCELLED POST MARKET | 00828610 |
| LIDOCAINE HCL AND DEXTROSE 5% INJ USP | 5 G / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | CANCELLED POST MARKET | 01935968 |
| LIDOCAINE HCL AND DEXTROSE 5% INJ USP | 400 MG / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | CANCELLED POST MARKET | 01935976 |
| LIDOCAINE HCL INJ 20MG/ML | 20 MG | LIQUID | INTERNATIONAL MEDICATION SYSTEMS LTD. | CANCELLED POST MARKET | 00565032 |
2 · Same class — other molecules in ATC C01BB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Lidocaine | 0.4% LIDOCAINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION · 0.4% LIDOCAINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION USP · LIDOCAINE 0.2% IN 5% DEXTROSE INJ · LIDOCAINE HCL 0.2% AND DEXTROSE 5% INJ · +8 more | 13 | 4 | Yes |
| Mexiletine | ALTI-MEXILETINE · MEXITIL CAP 100MG · MEXITIL CAP 200MG · MINT-MEXILETINE · +1 more | 8 | 4 | Yes |
| Tocainide | TONOCARD TAB 400 MG | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC C01B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| C01BC | Flecainide · Propafenone | 35 | 16 |
| C01BD | Amiodarone · Bretylium Tosilate · Dronedarone · Ibutilide | 43 | 14 |
| C01BA | Disopyramide · Procainamide · Quinidine | 44 | 1 |
| C01BG | Vernakalant | 1 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is LIDOCAINE HYDROCHLORIDE INJECTION called?
The same molecule, Lidocaine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Lignox | Latin | Saudi Arabia |
| VERSATIS | Latin | Bahrain, Czechia |
| Depo-medrol with Lidocaine | Latin | South Africa |
| Lidocaine Eva | Latin | Saudi Arabia |
| PLIAGLIS | Latin | Bahrain |
| Pliaglis® | Latin | United Arab Emirates |
| PRILA | Latin | Bahrain |
| Xylocaine | Latin | Bahrain, South Africa |
| xylocream® | Latin | United Arab Emirates |
| AVOCAINE | Latin | Bahrain |
| BelOcain vet. | Latin | Iceland |
| EMLA | Latin | Bahrain |
| Ennla | Latin | Saudi Arabia |
| Haemoproct | Latin | United Arab Emirates |
| Haemoproct Cream | Latin | United Arab Emirates |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.